Oh yeah, the crack R&D team that took a 30 year old essentially public domain off patent molecule (EPA) that is OTC in Japan with generic competition (EPADEL) and copied a 20 year old CVD study (JELIS) and tried to do the endzone run with it in the US market failed.... yeah... Im sure they totally "helped" develop MND-2119...
As for MND-2119's royalty... better know for sure that license transfers to the new owner in whole in the event of a buyout. Mochida would be dumb as hell to not have renegotiation clauses for that very event.
News 
Market Data 
Discover 
AI
